ABSTRACT
Hepatitis B virus (HBV) belongs to the Hepadnaviridae family. HBV infection may lead to acute and chronic hepatitis, which has become a global health issue. HBV capsid protein assembly modulators play an important role in multiple stages of HBV replication, such as encapsidation of pgRNA and synthesis of HBV DNA, thus becoming a new hotspot in the research and development of hepatitis B drugs. This paper reviews the research progress of HBV capsid protein assembly modulators.
ABSTRACT
HBV infection is a major public health threat around the world.At present, clinical anti-HBV drugs,including nucleoside/nucleotide analogues (NAs) and PegIFNα, can only directly or indirectly inhibit viral replication rather than viral elimination.In recent years, medical researchers and pharmaceutical enterprises are extensively researching and developing new drugs for treatment of HBV, and a variety of drugs have entered the stage of clinical trials.This article reviews the research progress on characteristics,safety and clinical trials,as well as the development trends of several currently available anti-HBV drugs, focusing on the target points and life cycle of HBV.
ABSTRACT
Up to date, there are two types of drugs approved to treat hepatitis B: interferons and nucleos (t) ide analogues. However, the therapies are limited in the clinical context because of the negative side effects of interferon-α and the development of substantial viral resistance to nucleos (t) idic inhibitors. Therefore, new drugs with novel structures and mechanisms are needed. In this article, the drugs approved by FDA or the European Commission for treating chronic hepatitis B virus infection, as well as those under clinical trials, and several compounds in preclinical studies are reviewed. Additionally, some potential targets and strategies to combat chronic hepatitis B virus infection are discussed.